NCT03450850View on ClinicalTrials.gov

Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

September 7, 2023

Study Completion Date

October 31, 2025

Conditions
Astrocytoma, Grade III
Interventions
DEVICE

NOVOTTF-200A

NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.

Trial Locations (1)

92868

University of California, Irvine, Orange

All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Daniela A. Bota

OTHER